Leaders in translating NET biology into novel therapies

Citryll has leveraged its deep understanding of the pro-inflammatory effect of neutrophil extracellular traps (NETs) to develop therapeutics for the treatment of a broad range of inflammatory diseases.

Next generation therapeutics for treatment of inflammatory diseases

Our lead antibody, CIT-013, is a next generation therapeutic for the treatment of inflammatory diseases. With a unique dual mode of action, CIT-013 has demonstrated a powerful ability to inhibit NETosis and the pathogenic consequences of NETs. It has anti-inflammatory properties across multiple preclinical disease models and inhibits NET release in human volunteers. CIT-013 is currently in Phase I clinical development, and Phase IIa studies in Rheumatoid Arthritis and Hidradenitis Suppurativa are expected to start later this year.

The role of NETosis and NETs in disease


The pathogenic role of NETs in inflammatory diseases has been demonstrated by an increasing body of scientific literature. Citryll has prioritized RA and HS as therapeutic development areas for CIT-013.

Latest News

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
Read More

Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO 

Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Read More

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Read More